Spectral Medical Inc. Stock Price - EDTXF

Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Spectral Medical Inc. EDTXF Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.001317 0.47% 0.2842 0.2842 0.2842 0.2842 0.282883 16:17:30
Bid Price Ask Price Spread Spread % News
0.281 0.302 0.021 6.95% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1 5,000 $ 0.2842 $ 1,421 3,411 0.162985 - 1.00
Last Trade Time Type Quantity Stock Price Currency
14:22:58 5,000 $ 0.2842 USD

Spectral Medical Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 64.18M 225.82M $ -3.94M - -16.29 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
178.40k $ - 0.00% - -

more financials information »

Spectral Medical Inc. News

Latest EDTXF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EDTXF Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.2980.2980.2828830.28514k-0.0138-4.63%
1 Month0.27460.298040.270.28114k0.00963.50%
3 Months0.25810.229390.27206k0.026210.16%
6 Months0.237210.22130.278214k0.04719.81%
1 Year0.272710.1629850.245018k0.01154.22%
3 Years0.825151.49940.1350.356540k-0.54095-65.56%
5 Years0.37041.49940.1350.454337k-0.0862-23.27%

Spectral Medical Inc. Description

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA), the only FDA-cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.


Your Recent History
USOTC
EDTXF
Spectral M..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.